Hope Rugo, Professor at City of Hope Comprehensive Cancer Center, shared on X:
“Binghe Xu presents data from the HEALER Trial in China evaluating anbenitamab (bispecific HER2ab) with lipo docetaxel vs THP for HER2+ MBC showing marked improvement in PFS and modest increase in heme tox.
Lipo docetaxel approved in US. Today published in NEJM!
Interesting to consider how this fits into the ADC TDXd world.”
You can also read: KEYNOTE-B49: Pembrolizumab Improves PFS but Not Overall Survival in PD-L1–Positive HR+/HER2− Advanced Breast Cancer
